Fat Loss
Overview
Fat loss peptides work through multiple distinct mechanisms: GLP-1/GIP receptor agonism for appetite and energy regulation, direct lipolysis stimulation, NNMT enzyme inhibition for metabolic activation, and mitochondrial upregulation. The most effective approaches combine appetite-suppressing peptides with metabolic rate enhancers and lean mass preservation strategies.
Recommended Peptides
- AOD-9604 – truncated growth hormone fragment (176-191); directly stimulates lipolysis in fat cells without IGF-1-mediated side effects; morning dosing preferred
- 5-Amino-1MQ – NNMT inhibitor; increases NAD+ levels, activates AMPK and SIRT1 pathways, and shifts fat cells toward energy expenditure
- Retatrutide – triple agonist with powerful appetite suppression and direct thermogenic effects via glucagon receptor
- Semaglutide – GLP-1 agonist reducing caloric intake and slowing gastric emptying; also improves insulin sensitivity
- Tirzepatide – dual GLP-1/GIP agonist with superior fat loss compared to semaglutide alone
- CagriSema – amylin + GLP-1 combination targeting complementary satiety pathways
- MOTS-C – mitochondrial peptide that improves fat oxidation and reduces lipid accumulation; exercise-mimetic
- SLU-PP-332 – ERR alpha/gamma agonist increasing mitochondrial biogenesis and fat burning capacity
- Tesamorelin – GHRH analogue particularly effective for visceral and hepatic fat reduction
- BAM15 – small molecule mitochondrial uncoupler; increases energy expenditure via proton gradient dissipation; reverses diet-induced obesity in preclinical models without affecting food intake or lean mass (NOT a peptide; preclinical only)
Protocols
Related Conditions
Research Summary
AOD-9604 demonstrated lipolytic and antilipogenic actions on isolated human adipose tissue (PMID-10950816) and does not interact with the GH receptor (PMID-11673763). 5-Amino-1MQ reversed diet-induced obesity in mice via NNMT inhibition (PMID-29155147). Semaglutide head-to-head vs liraglutide showed superiority (-15.8% vs -6.4%, STEP 8, PMID-35015037). Note: AOD-9604 and 5-Amino-1MQ evidence is entirely preclinical.
Related
#condition #metabolic-system